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Available online 17 February 2015As the number of people diagnosed with Alzheimer's disease (AD) reaches epidemic proportions, there is an ur-
gent need to develop effective treatment strategies to tackle the social and economic costs of this fatal condition.
Dozens of candidate therapeutics are currently being tested in clinical trials, and compounds targeting the aber-
rant accumulation of tau proteins into neuroﬁbrillary tangles (NFTs) are the focus of substantial current interest.
Reliable, translatable biomarkers sensitive to both tau pathology and its modulation by treatment along with
animal models that faithfully reﬂect aspects of the human disease are urgently required. Magnetic resonance
imaging (MRI) is well established as a valuable tool for monitoring the structural brain changes that accompany
AD progression. However the descent into dementia is not deﬁned by macroscopic brain matter loss alone:
non-invasive imaging measurements sensitive to protein accumulation, white matter integrity and cerebral
haemodynamics probe distinct aspects of AD pathophysiology and may serve as superior biomarkers for
assessing drug efﬁcacy. Here we employ a multi-parametric array of ﬁve translatable MRI techniques to charac-
terise the in vivo pathophysiological phenotype of the rTg4510 mouse model of tauopathy (structural imaging,
diffusion tensor imaging (DTI), arterial spin labelling (ASL), chemical exchange saturation transfer (CEST) and
glucose CEST). Tau-induced pathological changes included grey matter atrophy, increased radial diffusivity in
the white matter, decreased amide proton transfer and hyperperfusion.We demonstrate that the abovemarkers
unambiguously discriminate between the transgenic group and age-matched controls and provide a comprehen-
sive proﬁle of the multifaceted neuropathological processes underlying the rTg4510 model. Furthermore, we
show that ASL and DTI techniques offer heightened sensitivity to processes believed to precede detectable
structural changes and, as such, provides a platform for the study of disease mechanisms and therapeutic
intervention.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Introduction
Alzheimer's disease (AD) is a continuum of relentless irreversible
biochemical and pathological changes that lead to pronounced neuro-
degeneration. Factors implicated in the multifaceted pathogenesis in-
clude local inﬂammation (Akiyama et al., May-Jun, 2000), protein
accumulation (Fletcher et al., 2013), abnormal mitochondrial function
(Maruszak and Zekanowski, 2011) and haemodynamic alterations
(de la Torre, 2002) with amyloid plaques and neuroﬁbrillary tangles
(NFTs) being the classical hallmarks of the post-mortem AD brain.. This is an open access article underCurrently the most established methods for the biological assessment
of disease progression in patients are estimation of regional brain
atrophy using structural MRI, PET imaging of glucose metabolism
using ﬂuorodeoxyglucose (FDG) and imaging of amyloid deposits (e.g.
using [11C]-PIB or [18F]-Florbetapir) as well as invasive CSF sampling
to measure tau and amyloid moieties (Langbaum et al., 2013), all of
which target speciﬁc components of the pathobiological cascade. How-
ever, other detectable features of AD progression may exist that have
yet to be fully explored as potential imaging biomarkers and as such
may provide greater mechanistic insight into disease progression and
improve the scope of evaluation of emerging therapies. In this work
we sought to investigate new biomarkers of AD, sensitive to speciﬁc
tissue properties: perfusion, microstructure, chemical exchange and
glucose uptake. Speciﬁcally, we implemented the novel chemical
exchange saturation transfer (CEST) MRI for targeted detection ofthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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aggregated protein. The CEST method saturates mobile protons of the
macromolecular pool that are exchanging with the bulk water pool
(for recent reviews see Liu et al., 2013; van Zijl and Yadav, 2011). In
this study we used CEST to probe amide -proton transfer in grey matter
structures. We also implemented diffusion tensor imaging (DTI) (a sen-
sitive measure of local tissue inﬂammation and cellular integrity) to
probe changes inmicrostructural compartmentation. Finallywe applied
arterial spin labelling (ASL) and glucose CEST (glucoCEST) to measure
perfusion and glucose delivery and uptake to infer changes in cerebral
metabolism, vasculature and neuronal excitability and compare these
measures to the more established structural MRI biomarkers and
histology.
Transgenic mouse models are increasingly being used to further our
knowledge of the cause and progression of AD, and identify new targets
for therapeutic intervention (Chin, 2011; Games et al., 1995; Ramsden
et al., 2005; Spires et al., 2005).While nomouse recapitulates all charac-
teristics of the human condition, such models do permit the study of
speciﬁc pathological features in experimentally controlled conditions.
This is particularly advantageous in AD where human clinical research
can often be confounded by uncontrollable variables such as lifestyle
choices and other co-morbidity; mice allow the precise impact of
genes and their role in AD to be fully explored. Mice containing muta-
tions in the amyloid precursor protein (APP) gene are the oldest and
most widely studied models of AD, and are used to investigate the role
of APP, amyloid-beta and amyloidosis in neurodegeneration (Hall and
Robertson, 2012). APP and presenilin transgenic mice are also valuable
tools in preclinical drug discovery, where many of the emerging AD
treatments focus on decreasing amyloid-beta production and aggrega-
tion. However, while several of these compounds have shown promis-
ing preclinical results, they have had little to no success in clinical
trials. This may in part be due to the fact that while most APP mice
form plaques they do not have tangle pathology or evidence of robust
neurodegeneration. The failure of these candidate drugs to date to
show any improvements in the human condition has caused a shift in
interest to other therapeutic pathways (Clavaguera et al., 2009).
In recent years, tau has emerged as a potential target for therapeutic
intervention. Tau plays a critical role in the neurodegenerative process:
aggregates of hyperphosphorlylated tau forming neuroﬁbrillary tangles
(NFTs) are a major hallmark of AD and correlate with clinical disease
progression (Braak and Braak, 1991). In the absence of amyloid-beta,
NFTs are also implicated in several other neurodegenerative dis-
eases (frontotemporal dementia with parkinsonism, progressive
supranuclear palsey, corticobasal degeneration), further supporting
the role of tau in the dementing process (Lee et al., 2001). A mouse
model of tauopathy (rTg4510) has been developed that speciﬁcally ex-
presses tau in the forebrain but without amyloid plaques, enabling dis-
section of the unique role of tau in AD pathology (Ramsden et al., 2005;
Santacruz et al., 2005). Behavioural and histological studies of the
rTg4510 mouse have demonstrated cognitive deﬁcits in learning and
motor tasks andmarked atrophy of brain regions known to be selective-
ly vulnerable to AD such as the hippocampus and frontal cortex
(Santacruz et al., 2005).
In this study, we target diverse and speciﬁc components of tau
pathology by applying multi-parametric MRI to the rTg4510 model.
We show that each of the MRI methods can unambiguously discrimi-
nate tau pathology from healthy control subjects, providing a platform
for the longitudinal assessment of experimental treatments using
non-invasive imaging techniques. Furthermore, we demonstrate that
ASL and DTI metrics are sensitive to tau-pathology in regions of
low NFT density prior to signiﬁcant atrophy, providing evidence that
these data may inform the development of a multi-parametric imag-
ing biomarker for early detection of tau pathology in the clinic. This
is the ﬁrst application of ASL and CEST to the rTg4510 model as
well as the ﬁrst report of glucoCEST to investigate neurodegenerative
disease.Materials and methods
Transgenic mice
Generation of homozygous rTg4510 transgenic mice has been
reported previously (Ramsden et al., 2005). Female rTg4510 mice
were licensed from the Mayo Clinic (Jacksonville Florida, USA) and
bred for Eli Lilly by Taconic (Germantown, USA). Mice were imported
to the UK for imaging studies at the Centre for Advanced Biomedical Im-
aging (CABI), London. All studies were carried out in accordance with
the United Kingdom Animals (Scientiﬁc Procedures) act of 1986.
Magnetic resonance imaging
All imaging was performed with a 9.4 T VNMRS horizontal bore
scanner (Agilent Inc.). A 72 mm inner diameter volume coil (Rapid
Biomedical) was used for RF transmission and signal was received
using a 4 channel array head coil (Rapid Biomedical). Mice were
anaesthetised under 2% isoﬂurane and positioned in a MRI compatible
head holder to minimise motion artefacts. Anaesthesia was then
maintained at 1.5% isoﬂurane in 100% O2 throughout imaging. Core
temperature and respiration were monitored using a rectal probe
and pressure pad (SA instruments). Mice were maintained at ~37 °C
using heated water tubing and a warm air blower with a feedback
system (SA instruments).
In this study, two separate cohorts of both rTg4510 and wild-type
litter matched control mice at 8.5 and 9.5 months of age were imaged.
In theﬁrst cohort (8.5months)we conducted ASL, DTI and3D structural
imaging to N = 9 rTg4510 mice and N = 17 wild-type controls. The
brains of each of the rTg4510 and wild-type mice were perfused ﬁxed
for histology directly after imaging (see Perfuse ﬁxation). In the second
cohort (9.5 months) we acquired CEST data from N = 10 rTg4510 and
N = 9 WT mice and gluco-CEST data from N = 5 rTg4510 and N = 5
wild-type control mice that were fasted for 24 h prior to the imaging
experiment. The reported p-values are from standard t-tests for differ-
ences in parameters between the rTg4510 andWT groups, unless stated
otherwise.
Structural imaging and processing for Tensor Based Morphometry (TBM)
A 3D T2-weighted sequence was employed for structural
imaging with parameters: FOV = 19.2 mm × 16.8 mm × 12.0 mm;
resolution = 150 μm × 150 μm × 150 μm; TR = 2500 ms, TEeff =
43ms, ETL = 4, NSA= 1. In order to estimate the volume of the cortex
and hippocampus, ROIs were delineated using open source software
(ITK-SNAP). ROIs across all slices containing the hippocampus were
manually drawn by the same expert with visual reference to a mouse
brain atlas.
For TBM analysis, in-vivo structural images were automatically
oriented to a standard atlas space (Right Antero-Superior), corrected
for intensity non-uniformity using the N3 algorithm (Sled et al., 1998),
and skull stripped using a STAPLE algorithm (Cardoso et al.,2013) to
combine masks from several prior atlases registered to the data.
Intensities were normalised (Nyul et al., 2000) and a multi-iteration
group-wise registration (implemented in the open-sourceNiftyReg soft-
ware Modat et al., 2010) was performed as follows to align equivalent
voxels between subjects. First, all subjects were rigidly aligned to a
randomly-chosen target member of the group. This was followed by
four iterations of afﬁne registration (12 degrees of freedom), using a
block-matching algorithm based upon normalised mutual information,
and 20 iterations of non-rigid registration (NRR), based upon symmetric
free-form deformation. After each iteration, the intensity average image
was found and used as the target for the subsequent registration. Defor-
mation ﬁelds were transformed by taking the log of the determinant of
the Jacobianmatrix calculated at each voxel, to give that voxel's relative
expansion or contraction in the ﬁnal average image compared to each
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kernel to account for registration error and to render the values closer
to a normal distribution, and mass-univariate statistics (two-tailed
t-tests) were performed on each voxel, ﬁtting a General Linear model
controlling for total intracranial volume (TIV) based upon the brain
masks. The resulting statistical parametric map was corrected for
multiple tests using the False Discovery Rate (FDR (Genovese et al.,
2002), q = 0.05). We applied a cluster size threshold of 20 voxels.
Arterial spin labelling (ASL) to image cerebral perfusion
A ﬂow-sensitive alternating inversion recovery (FAIR) sequence
(Kim, 1995; Kwong et al., 1992) with a 4-shot segmented spin-
echo echo-planar imaging (EPI) readout was implimented with
the following parameters: 5 slices, slice thickness = 1 mm, FOV =
20 × 20 mm, matrix size = 64 × 64, slice selective inversion pulse
width = 12 mm, 5 inversion times (TI = 600, 1250, 1500, 2000,
2500 ms), TE = 11 ms, TR = TI + 2 s. A hyperbolic secant adiabatic
inversion pulse was used with a bandwidth of 20 kHz for the FAIR
labelling pulses (Wells et al., 2012). T1 maps were also acquired using
an inversion recovery SE-EPI sequence for cerebral blood ﬂow (CBF)
quantiﬁcation. The splenium of the corpus callosumwas used as a land-
mark for consistency of slice positioning between subjects. CBF and ar-
terial transit time (δa) maps were generated by ﬁtting the ASL images
and T1 maps to the model described by Buxton et al. (Buxton et al.,
1998). ROIsweremanually drawn in the cortex, hippocampus and thal-
amus across two 1 mm thick slices matching the regions that
underwent histological analysis of NFT density (Fig. 1(I)). A ROI across
the two most rostral slices in the frontal cortex was also drawn
(where hyper-perfusion of the rTg4510 brains was particularly appar-
ent from visual inspection).
Diffusion tensor imaging (DTI)
A four shot Spin Echo EPI sequence was used to acquire sixteen
slices. The olfactory bulbs were used as an anatomical landmark to
maintain consistency in slice positioning between animals. The FOV
was 20 × 20 mmwith a matrix size of 100 × 100 and a slice thickness
of 0.5 mm. Diffusion gradients were applied in thirty directions with
the following parameters G = 0.25 T/m, Δ= 9.3 ms, δ= 5.5 ms, and
b = 1050 s/mm2 to generate diffusion weighted images in addition to
a single unweighted B0 image. Acquisition of 5 averages with a TR of
2000ms gave a total imaging timeof 43min. Softwarewritten inMatlab
was used to construct tensors at each voxel through a least squares
solution approach (Batchelor et al., 2003). The parameters MD, FA as
well as radial and axial diffusivity were calculated from the tensors fol-
lowing standardmethods (Le Bihan et al., 2001; Song et al., 2002). Three
slices posterior to the bregma were selected in the unweighted images
and ROIs were manually drawn in the corpus callosum and grey matter
areas of the hippocampus, cortex and thalamus (Fig. 1(I)). It should be
noted that unlike ASL and CEST techniques (which suffer from relatively
low SNR), DTI data were acquired with sufﬁcient spatial resolution to
resolve the corpus callosum and hence only DTI parameters from the
white matter are reported. Furthermore, radial and axial diffusivity
were only calculated in white matter structures. Mean values were cal-
culated for the ROIs in each group for comparison of theDTI parameters.
Chemical exchange saturation transfer (CEST)
The CEST sequence was acquired using a single slice gradient
echo imaging sequence (TR = 6.1 ms, TE = 2 ms, ﬂip = 5°, FOV =
20 × 20 mm2, slice thickness 3 mm, matrix size = 64 × 64). Saturation
pulseswere applied at 79 frequency offsets covering±6ppm to encom-
pass amide proton transfer (APT) saturation peaks around +3.5 ppm.
A reference offset at 200 ppm was also acquired for normalization.
Shimming was performed across the entire imaging slice (3 mmthickness). ATP was calculated as the area under the MTRasym curves
between 3.3 and 3.7 ppm on a pixel-by-pixel basis by ﬁtting a polyno-
mial function to Z spectra, correcting for off-resonance effects by cubic
spline interpolation and subtracting the signal intensities at either
side of the direct water saturation peak (van Zijl and Yadav, 2011b).
ROIs were manually drawn in the cortex, hippocampus and thalamus.
Glucose chemical exchange saturation transfer (glucoCEST)
CEST measurements (using identical parameters described above),
were applied at baseline and then every 8min following an intraperito-
neal injection of 1 g/kg glucose for a total of 100 min following glucose
delivery. To measure the in-vivo glucose uptake the chemical exchange
contaminating effects are removed by subtracting pre-injection from
post-injection and measuring all of the area under the MTRasym curve
(Chan et al., 2012; Nasrallah et al., 2013; Walker-Samuel et al., 2013).
ROIs were taken in the thalamus, cortex and hippocampus to match
the regions that underwent histological analysis of NFT density (see
Fig. 1(I)).
Perfuse ﬁxation
Following in vivo imaging, animals were terminally anaesthetised
with Euthanal (0.1 mL) administered via intraperitoneal injection. The
thoracic cavities were opened and the animals perfused through the
left ventricle with 15–20 mL of saline (0.9%) followed by 50 mL of
buffered formal saline at a ﬂow rate of 3 mL per minute. Following
perfusion, the animal was decapitated, deﬂeshed, and the lower jaw re-
moved. All brains were stored in-skull at 4 °C before being dispatched
for histology.
Histology and immunohistochemistry
Brain samples were then processed using the Tissue TEK® VIP
processor (GMI Inc,MNUSA). After processing, sectionswere embedded
in parafﬁn wax to allow coronal brain sections to be cut. Serial sections
(6-8 mm) were taken from using HM 200 and HM 355 (Thermo
Scientiﬁc Microm, Germany) rotary microtomes.
Immunohistochemistry (IHC) was performed using a primary
antibody for tau phosphorylated at serine 409 (PG-5; 1:500 from
Peter Davies, Albert Einstein College of Medicine, NY, USA). Secondary
antibody was applied and slides were then incubatedwith avidin biotin
complex (ABC) reagent for 5 min (M.O.M. kit PK-2200, Elite ABC rabbit
kit PK-6101, or Elite RTU ABC PK-7100 Vector Labs). After rinsing, slides
were treated with the chromogen 3,3′-diaminobenzidine (DAB; Vector
Laboratories, SK-4100) to allow visualisation. The slides were then
cover slipped, dried and digitised using an Aperio Scanscope XT (Aperio
Technologies Inc., CA, USA).
Ex vivo image analysis and quantiﬁcation
Imageswere viewed and analysedwith Aperio ImageScope software
(version 10.2.2319). In each study, two sections for each mouse were
analysed. For each section stained, areas of speciﬁc interest (in this
case the cortex, hippocampus and thalamus) were delineated in the
same way as they were for the MR imaging and their area ascertained
in mm2. Within these areas of interest, the number density of PG5
immunoreactivity was quantiﬁed using AperioImageScope.
In order to investigate the relationship between histological mea-
surements of tau load and quantitative MRI, we performed two levels
of correlation analysis. Firstly, for each region, NFT density was correlat-
ed to each of the MR metrics across the 9 rTg4510 subjects using
Pearson's correlation. However, given limited evidence for within re-
gion correlations, we additionally performed a between region, ranked
correlation analysis. rTg4510 brain regions were ranked as 0 (wildtype
control mice), low (thalamus of rTg4510 mice) and high (cortex and
Fig. 1.High resolution structural MRI. A–F) Results from structural analysis, showing TBM statistical results through representative coronal and axial slices of the ﬁnal average image after
20 iterations of NRR (locations indicated on schematic diagram above). Red: TG4510 brains relatively locally smaller than the average; blue: larger. Based upon FDR-corrected t-statistics
(q=0.05), controlling for total intracranial volume. Clusters smaller than 20 voxelswere removed. CB: cerebellum; CX: cortex; EC: entorhinal cortex; H: hippocampus;MB:midbrain;OB:
olfactory bulbs; TH: thalamus; V: Ventricles. G) Manually segmented hippocampal volumes (WT and TG), boxplots report median, interquartile range and range. H) Comparison of
manually segmented hippocampul volume (rTg4510) to PG positive NFT density, where a signiﬁcant negative correlation was observed (Pearson's correlation coefﬁcient = 0.81, p = 0.01).
I) Typical manual grey matter ROIs used to report average ASL, DTI, CEST, GlucoCEST from the cortex (blue), hippocampus (red) and thalamus (green), overlaid on the average image.
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percentage change in each of theMR parameters in each of the individual
animals was calculated relative to the mean value of the WT controls, in
order to account for intrinsic regional differences. Correlations in %
change inCBF,MD, FA, CEST (fromsecond cohort) against ranked tau bur-
den (assigned 0 (WT), 1 (low) and 2 (high)) were investigated using
Spearman's rank correlation coefﬁcient. It should be noted that correla-
tion of DTI metrics in the white matter to histology was not performed
as there is no PG5 positive cell staining detected in the corpus callosum.
Measurement of blood pressure and heart rate in awake and anaesthetised
conditions
Measurements of heart rate and blood pressure were performed in
a separate cohort of rTg4510 and WT control mice in awake and
anaesthetised conditions. The primary motivation for acquiring these
data followed the observation of marked hyperperfusion in the rTg4510mice (see Results), a somewhat counter intuitive ﬁnding. Speciﬁcally
we were interested to investigate whether increased CBF in the rTg4510
cohort could be partially explained by elevated blood pressure and
heart rate under isoﬂurane anaesthesia compared to the WT controls.
The differences inmean arterial pressure (MAP) and heart rate between
WT rTg4510 mice studied under both conscious and anaesthetized
conditions were carried out on animals purchased from Taconic with
surgically-implanted telemetry devices. Conscious telemetry collec-
tions were performed continuously from all (non-anaesthetized)
animals for 25 h to assess mean arterial pressure and heart rate. The
mean cardiovascular data for each animal was calculated for 1-hour av-
erages from the logging period data. To assess unconscious parameters,
the animals were anaesthetized by placing the animal in a nose cone
connected to a steady ﬂow of 1.5% isoﬂuorane and oxygen at 1 L/min,
warmed with a water blanket maintained at 37 °C, and maintained
under anaesthesia for approximately 1.5–2 h. Unconscious telemetry
data were collected continuously starting immediately after and for
373J.A. Wells et al. / NeuroImage 111 (2015) 369–378the duration of anaesthesia. The mean arterial pressure and heart rate
for each animalwas calculated for 15-minute averages from the logging
period data.
Results
High resolution structural MRI
High resolution (150 μm3) T2-weighted structural imaging was
applied to investigate the morphometric phenotype of the rTg4510
model in comparison to WT controls. Measures of macroscopic brain
atrophy conﬁrmed regional brain shrinkage reﬂecting elevated NFT
deposits.Manual segmentation of the hippocampus showed a signiﬁcant
difference between transgenic and wildtype animals (normalising to
total intracranial volume (TIV) p = 2 × 10−11, effect size = 5.5
(Fig. 1G)).
The TBM method allowed second-order voxel-wise group differ-
ences in brain atrophy to be elucidated, where gross differences in
brain size are corrected for in the image alignment and normalisation
procedure. Fig. 1(A–F) shows representative slices through the group
average image with TBM statistics overlaid. Extensive bilateral changes
throughout the transgenic brain relative to the group average were
observed, including substantial atrophy of the striatum and dilation of
the lateral, third and fourth ventricles. TBM also detected signiﬁcant
bilateral hippocampal atrophy and local contraction within the cortex
and forebrain of the transgenic population.
Quantitative MRI discriminates tau pathology
To investigate whether emerging quantitative MRI techniques could
detect tau-driven differences in the rTg4510 model (relative to the WTFig. 2.QuantitativeMRImeasurements that discriminate tau pathology fromwildtype controls.
of theMRI parameters across the rTg4510 andWTmice with individual outliers highlighted by
frontal cortex; 3rd row: The CEST APT signal in the hippocampus; 4th row: glucoCEST signal in
representative WT (2nd column) and rTg4510 (3rd column) mouse.controls), we applied ASL, CEST, DTI and glucoCEST to rTg4510 andWT
control subjects. We observed a multi-parametric pattern of changes
that differentiated the tau model from the healthy brain and were
particularly pronounced in selective brain regions. Fig. 2 shows data
from each technique in regions where complete discrimination was
observed between the rTg4510 and WT subjects. The rTg4510 mice
had increased radial diffusivity in the corpus callosum (p = 1.6 × 10−8,
effect size = 3.8), increased CBF in the frontal cortex (p = 7.4 × 10−10,
effect size = 3.8), decreased amide proton transfer (APT) in the hippo-
campus (p = 1.16 × 10−10, effect size = 4.5) and increased glucoCEST
signal in the cortex (p = 0.01, effect size = 2.6). Signiﬁcant increases
in CBF andMDwere observed in the cortex, hippocampus and thalamus
of the rTg4510mice. Signiﬁcantly reduced APT signal and increasedMD
and FA was observed in the cortex and hippocampus but no signiﬁcant
differences in these parameters were found in the thalamus. Increased
glucoCEST was recorded in the cortex although no signiﬁcant differ-
ences were detected in other regions. The raw CBF, APT, MD and FA
values for each grey matter region are given in the supplementary
material.
Regional correlations of quantitative MRI to NFT density
Immunohistochemistry was performed on each of the individual
rTg4510 (n = 9) and WT (n = 17) control animals to estimate the
density of PG-5 positive NFTs in cortical, hippocampal and thalamic
regions (Fig. 3). NoPG-5positive cellswere observed in any of the control
mice and quantitative measures were made in the hippocampus, cortex
and thalamus for each rTg4510 mouse. We observed a signiﬁcant
correlation between hippocampal volume and NFT density (Pearson's
correlation coefﬁcient (CC) = 0.81, p = 0.01) (Fig. 1H). In contrast, we
found no correlation between cortical volume and cortical NFT density1st column: Box andwhisker plots representing themedian, interquartile range and range
a red cross. 1st row: The radial diffusivity in the corpus callosum; 2nd row: The CBF in the
the cortex. 2nd/3rd column: Maps of radial diffusivity, CBF, CEST APT and GlucoCEST in a
Fig. 3. Immunohistochemistry to estimate regional PG-5 positive NFT density. A) Single slice from a representative rTg4510 mouse with staining for PG-5 positive NFTs. Marked regional
dependence of NFT density is observable (see inset (B–D) for examples of cortical, hippocampal and thalamic NFT distribution). E) Quantitative regional estimates of NFT density for each
of the 17 WT and 9 rTg4510 mice that underwent MRI (8.5 month age).
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accumulation of NFTs in both hippocampus and cortex. Indeed, lim-
ited within region correlations were observed using CBF, DTI and CEST
basedmetrics. Therefore, a secondary correlation analysis was performed
inwhich the cortex and hippocampuswere ranked as “high” pathological
tau burden (mean NFT density = 229 cells/mm2 and 83 cells/mm2
respectively) and the thalamus as “low” tau burden (mean NFT density
2.3 cells/mm2) (Fig. 3). When we examined the relationship between
percentage difference in MRI parameters fromWT controls (ranked as
0 tau burden) and tau density, we observed a signiﬁcant correlation of
CBF, APT, FA and MD to the ranked data (Fig. 4). There was a positive
correlation of CBF (Spearman's CC = 0.78, p = 1.5 × 10−16), FA
(Spearman's CC = 0.48, p = 1 × 10−5) and MD (Spearman's CC =
0.57, p= 1.2 × 10−7) to group ranked tau density with CEST displaying
a negative relationship (Spearman's CC = 0.8, p = 4.7 × 10−14).
However, similarly to the structuralmeasurements, therewas no statis-
tical difference in the percentage difference from control between the
cortex and hippocampus (the “high” ranked regions) in each of the
MR measures, despite the cortex presenting with a threefold increase
in NFT density relative to the hippocampus. This ﬁnding suggests
a monotonic relationship exists between measures of CBF, APT, MD,FA and NFT density within a degree of tau burden which dissociates
between regions of “high” tau burden (the cortex and hippocampus)
in the 8.5 month rTg4510 mice.
CBF and MD increases in the thalamus
The thalamus presented with relatively “low” NFT density at
this time point (2.3 cells/mm2) and no signiﬁcant atrophywas detected
with TBM (see above). Yet, we observed increased CBF (p = 3 × 10−6)
andMD (p=0.04) in the thalamus of the rTg4510 cohort relative toWT
control mice (Fig. 5). Whilst the interpretation of these data is complex
due to the more severe pathology in the surrounding, functionally
connected, regions (see Discussion), this does provide some encour-
agement that such techniquesmay provide sensitivity tomore subtle
tau-induced pathology that proceed gross morphometric changes.
Diffusion tensor imaging of white matter
DTIwas employed to investigatemicrostructural changes in thewhite
matter of the rTg4510 mice relative to the normal brain. The mean ROI
measurements of FA and MD in the corpus callosum showed signiﬁcant
Fig. 4.QuantitativeMRI correlates to histological ranking of PG-5positiveNFTdensity. Percentage difference (normalised to control) inA)CBF, B)APT ratio C)MDandD) FA as a function of
histological ranking of PG-5 positive NFT density. Spearman's non-parametric correlation coefﬁcient was used to investigate a possible correlation of quantitative MRI to histological
ranking (p-value and correlation coefﬁcient (CC) reported in ﬁgure inset). Boxplots representmedian, interquartile range and range of percentage difference in quantitativeMR estimates
fromWT control with individual outliers highlighted by a red cross.
375J.A. Wells et al. / NeuroImage 111 (2015) 369–378differences between the transgenic and control groups (Fig. 6). The trans-
genic group exhibited a reduced FA of 0.32 ± 0.05 compared to the
controls (0.48 ± 0.07, p = 4.5 × 10−6, effect size = 2.7). In contrast,
the MD of 9.4 ± 0.8 × 10−4 mm2/s observed in the transgenicFig. 5. CBF andMD in theWT and rTg4510 thalamus (region of “low” tau density). ASL CBF
(A) and MD (B) estimates in theWT and rTg4510 thalamus (region of “low” tau density).
Boxplots represent median, interquartile range and range with individual outliers
highlighted by a red cross.group was greater than in the controls (7.7 ± 0.4 × 10−4 mm2/s, p =
6.3 × 10−8, effect size = 3). Most marked was radial diffusivity, inFig. 6. Diffusion tensor imaging measurements in the white matter (corpus callosum) of
rTg4510 and WT controls. DTI measurements in the white matter (corpus callosum) of
rTg4510 and WT controls. Boxplots represent median, interquartile range and range
with individual outliers highlighted by a red cross.
376 J.A. Wells et al. / NeuroImage 111 (2015) 369–378which we saw a clear discrimination between the wildtype and the
transgenic groups (p = 1.5 × 10−8, effect size = 3.8) (Fig. 2, ﬁrst
row). This separation did not occur in the axial diffusivity values
where there was no signiﬁcant difference between groups
(rTg4510 = 11.1 ± 0.9 × 10−4 mm2/s, control =10.7 ±
0.9 × 10−4 mm2/s, p = 0.36).
Blood pressure and heart rate under awake and anaesthetised conditions
rTg4510 mice had higher mean arterial pressure (MAP) and heart
rate compared to the wild type mice during the active 12-hour dark
phase of the 24-hour conscious study interval. The average difference
in MAP between groups was 17.4 mm Hg, with a maximum difference
at the 9th hour of 24.1 mm Hg ± 5.5 and a minimum difference at the
12th hour of 9.0 mm Hg ± 6.5. The average difference in the heart
rate between groups was 142 bpm, with a maximum difference at the
6th hour of 183 bpm ± 27 and a minimum difference at the 12th
hour of 68 bpm ± 24. No differences were noted in these parameters
during the light cycles. In contrast, in the same mice anaesthetized for
a 2 hour period under comparable conditions used in the MRI experi-
ments, no signiﬁcant differences in MAP or heart rate were measured
between wildtype (WT) and rTg4510 groups.
Discussion
This study reports the ﬁrst application of non-invasive imaging bio-
markers, sensitive to perfusion, protein accumulation, glucose uptake
and tissuemicrostructure to generate a multi-parametric tissue charac-
terisation of tau pathology. We have demonstrated the sensitivity of
non-invasive imaging to provide brain tissue correlates of tau pathology
in white matter and in regions of high NFT density in the grey matter.
Hyperperfusion and increased MD were observed in a region of low
NFT density with no detectable structural changes. This ﬁnding demon-
strates the value of ASL andDTI for the identiﬁcation of tau-driven path-
ological processes prior to marked atrophy, suggesting their utility as
biomarkers for the early assessment of novel tau therapeutics.
Histologicalmeasures of pathological tau burden in the rTg4510mice
demonstrated a strong regional dependence of NFT density ranging from
low (2.3 counts/mm2 in the thalamus) to high (229 counts/mm2 in the
cortex) (Fig. 3). This is to be expected as expression of tau is driven by a
forebrain speciﬁc promoter (CaMKII) in the rTg4510 mouse (Ramsden
et al., 2005). We sought to exploit this marked dynamic range of NFT
density (as quantiﬁed using PG-5, pS409 tau) between regions to inves-
tigate correlations between ranked tau burden and difference in MR
parameters from control (to account for intrinsic regional differences).
We observed signiﬁcant correlations between the percentage change
from control in CBF, MD, FA and CEST across regions free of NFTs
(wildtype), low NFT density (rTg4510 thalamus) and high NFT density
(rTg4510 cortex and hippocampus), indicating a monotonic relation-
ship between NFT density and quantitative MR changes between
different regions of varying tau load at this time point. This observation
provides encouragement that multi-parametric quantitative MRI could
be used to broadly classify regions of negligible, low and high NFT
density for non-invasive staging of AD. The percentage change in MR
parameters in rTg4510 from control were very similar between the cor-
tex andhippocampus (high ranked data), despite themarked difference
in the overall NFT density between these two brain regions. Thismay be
a feature of the rTg4510 model at this time point or reﬂect the greater
and more selective vulnerability (or different inherent composition)
of the hippocampus, a region known to presentwithmarked abnormal-
ity in AD patients. Manual volumetric estimates of the hippocampus
showed the strongest within-region correlation to NFT density (Fig. 1)
indicating a strong link of NFT formation and hippocampal atrophy at
this time point. We observed limited within-region correlations of
NFT density to other quantitative MR parameters which may be due
to the relatively narrow distribution of NFT density within each region(Cortex: 229 (±28), Hippocampus: 82.9 (±15), Thalamus: 2.3
(±0.8)) at this time point. Longitudinal characterisation of this model
using multiple quantitative MRI parameters would be valuable to un-
derstand the regional nature of the temporal progression of changes
across the individual imaging modalities. It could be that the relation-
ship between PG-5 positive NFT density and individual MRI parameters
would be stronger at particular stages in the progression of tau pathol-
ogy (for example as tangles begin to form in themodel at 4–6months of
age). It should be noted that a limitation of this study is the division of
the applied techniques into two separate cohorts of rTg4510 and con-
trol mice of subtlety different ages (8.5 and 9.5 months). Structural im-
aging, ASL and DTI were acquired in the ﬁrst cohort (imaging time 2 h,
45min) and Glucose CEST and CESTwere acquired in the second cohort
(imaging time ~ 1 h, 40min). Furthermore, the relatively late time point
(8.5–9.5months)may restrict evidence for speciﬁcity ofMRparameters
to abnormal tau within the high ranked regions, as marked neurode-
generation is likely to have already occurred. Future application of
these techniques at earlier time-points in the rTg4510 and alternative
mouse models of AD may help elude a multi-parametric MRI signature
with high speciﬁcity to tau pathology.
Structural MRI has already established itself as a reliable biomarker
in the clinical diagnosis of Alzheimer's disease (Dubois et al., 2007;
Frisoni et al., 2010; Jack et al., 1997); characteristic greymatter reduction
and ventricular enlargement can be visualised using standard
T1-weighted sequences. As well as revealing signs of atrophy, which
can inform differential diagnosis of the disease, antemortem MRI has
previously been found to correlatewell withmeasures of cognitive dete-
rioration and post-mortem Braak staging of the disease (Csernansky et
al., 2004; Jack et al., 2002; Vemuri et al., 2008; Whitwell et al., 2008).
The pattern of brain atrophy is closely related to regional NFT
accumulation found in AD patients (and quite different to the pattern
of amyloid plaques) (Braak and Braak, 1991; McDonald et al.,
2009), and thus atrophy remains a valuable biomarker in the evalu-
ation of tau based therapeutics. The rTg4510 mouse mimics the fea-
tures of clinical neurodegenerative diseases such as Alzheimer's
disease with cognitive deﬁcits, NFT formation and neuronal loss in the
forebrain and hippocampus (Ramsden et al., 2005; Santacruz et al.,
2005). Previously published work has reported structural changes in
rTg4510 mice in the hippocampus and cerebral cortex, as well as en-
largement of the ventricles using in vivoMRI (Yang et al., 2011). Using
TBM,wewere able to extend these observations and additionally detect
local volume reductions in the cortex, hippocampus, caudate putamen
(striatum) and olfactory bulbs as well as ventricular expansion
(Fig. 1A–F). Thesemorphometric changes coincide with NFT pathology,
thereby supporting the role of tau in neurodegeneration. At this time
point, the transgenic brains have undergone gross atrophy which is no-
ticeable by eye in in-vivo structural scans. We therefore anticipate that
TBM will most valuable in the detection of subtle structural abnormali-
ties that occur at earlier stages of tauopathy. The negative correlation
that we measured between hippocampal volume and NFT density pro-
vides evidence of a direct relationship betweenNFT pathology and atro-
phy, whilst highlighting the sensitivity of in-vivoMRI to subtle volume
changes. This correlation was not present in the cortex, despite higher
NFT density. This may be because the hippocampus has a more rapid
progression of tangle formation and thus the subsequent neurodegen-
eration is more advanced at 8–9 months of age.
AD patients and subjects in prodromal disease stages present with
regionally dependent hypo- and hyper-perfusion (Wolk and Detre,
2012) compared to healthy control subjects. In this work we have ob-
served increased CBF in the rTg4510 mice, which correlated with rank-
ing of tau burden across different brain regions (Fig. 4). There is a
paucity of studies that have applied ASL to mouse models of AD, al-
though cortical hypo-perfusion has been reported in two amyloid
models (Faure et al., 2011; Weidensteiner et al., 2009). Our contrasting
result (when applying ASL to a mouse model of tau pathology for the
ﬁrst time) may give clues into the different mechanisms underlying
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neuronal excitability (Palop et al., 2007), neural compensatory mecha-
nisms (Wierenga et al., 2011) or a breakdown of auto-regulation, though
we do not have evidence that alludes to onemechanism at this point. The
similarity of the blood pressure measurements in the anaesthetised
rTg4510 and wildtype animals indicates that systemic differences in BP
are not responsible for the elevated CBF in the rTg4510 animals, and
that the observed hyper-perfusion is brain speciﬁc.
A number of clinical studies using DTI have observed increased MD
and reduced FA in the white matter of the brains of AD patients when
compared to healthy controls (Jack et al., 2012; Sabbagh et al., 2013).
Our ﬁndings of increased MD and reduced FA in rTg4510 mice relative
to wild type controls are consistent with this and suggest that the aber-
rant white matter microstructure observed in AD may be, at least in
part, a consequence of the tau pathology underlying the disease. Our ob-
servation of a signiﬁcant increase in radial diffusivity in the presence of
unchanged axial diffusivity in the corpus callosum of the rTg4510 mice
is consistent with this and suggests a reduction in myelination, mirroring
previous observations in sub regions of the corpus callosum in AD suf-
ferers (Di Paola et al., 2010). These ﬁndings are highly concordant with
an earlier longitudinal study that applied DTI methods to investigate the
whitematter of the rTg4510model (Sahara et al., 2014). Electronmicros-
copymeasureswere performed and demonstrated the presence of tau in-
clusions in the white matter and subsequent micro-structural
disorganisation relative to WT controls at later time points (Sahara et
al., 2014). The effects of amyloid plaques, the other hallmark pathology
of AD, have been investigated in previous studies (Song et al., 2004; Sun
et al., 2005) where differences in DTI parameters have been observed at
late time points after the appearance of amyloid plaques. Abnormal
myelination patterns have been identiﬁed prior to appearance of NFTs
and amyloid plaques in a mouse model exhibiting both pathologies
(Desai et al., 2009). The MD measurements in grey matter regions are
in good agreement with previous studies that have detected elevated
values in the brains of AD patients (Fellgiebel et al., 2004; Kantarci et
al., 2001; Rose et al., 2008) and in mouse models exhibiting amyloid pa-
thology at late stages of progression (Sun et al., 2005). The positive cor-
relation between the increasedMD and the tau density ranking suggest
that the disruption to the cytoarchitecture indicated by these increases
may be driven by the pathology. Furthermore, the positive correlation
of FA with tau density may indicate that the structural reorganisation
that occursmay have directional speciﬁcity. FA has been found to be re-
duced in AD patients in the hippocampus (Fellgiebel et al., 2004) and
the thalamus (Rose et al., 2008) which contradicts the ﬁndings in this
studywhere the FAwas increased signiﬁcantly in the cortex and hippo-
campus in the transgenic mice and there is no signiﬁcant difference in
the thalamus. These differences may be due to the addition of amy-
loid-beta pathology present in the brains of AD patients or the inherent
differences in murine grey matter tissue structure.
Magnetisation transfer ratio has been studied in clinical Alzheimer's
disease (Hentschel et al., 2004; van Es et al., 2006). CEST MRI differs
from magnetization transfer studies by probing the chemical exchange
in mobile compounds rather than semisolids (van Jijl and Yadav, 2001).
Contrast in CEST APT-weighted imaging is provided by the exchange of
amide protons in mobile cellular proteins and peptides with water pro-
tons. The reduction in APT in the rTg4510 animals may indicate a break
down in normal chemical exchange caused by tau pathology. However
thedifferences in APTmay also be inﬂuenced bypH and the longitudinal
relaxation time (T1), which may change due to cell death, for example
(van Zijl and Yadav, 2011), meaning that as a biomarker, CEST distin-
guishes normal controls from rTg4510 mice but does so in a non-
speciﬁc manner.
GlucoCEST was also able to discriminate between tau pathology and
normal tissue. Given its reliance on the injection of normal, unlabelled
glucose, this novel technique has potential for translation into a clinical
setting to diagnose and track the progression of neuro-degeneration,
without the associated exposure to radiotracers required for PETimaging. In this work we observed an increased glucoCEST signal in
the cortex of the rTg4510 mice relative to WT controls. This ﬁnding is
supported by a recent study that reported increased glucose utilisation
and hyper-metabolism in the cortex in the same mouse model (Nilsen
et al., 2013). However, the glucoCEST signal arising from free glucose
and products arising from its metabolism can be present in any of
three tissue compartments: intravascular, extravascular–extracellular,
and intracellular (Chan et al., 2012; Nasrallah et al., 2013;
Walker-Samuel et al., 2013). The increased cortical glucoCEST signal
that we measured in the rTg4510s could therefore be caused by
increased accumulation of glucose in the tissue due to a reduction in
glucose metabolism alongside an increased delivery due to the elevated
CBF to the cortical regions. The technique's ability to clearly distinguish
tau pathology is the ﬁrst application to neuro-degeneration and pro-
vides further insight into the metabolic processes of the tau pathology.
The thalamus of the rTg4510 mice was found to have relatively low
NFT density (mean=2.3 cells/mm2)with no detectable atrophy (based
on TBM), mirroring human tissue at early Braak staging with low NFT
density (Whitwell et al., 2008). We observed an increased CBF and
MD in this region relative toWT controls. This ﬁnding suggests that mi-
crostructural and haemodynamic changes that occurwithout gross neu-
ronal loss can be detected in this brain region with MRI and highlights
the value ofmulti-parametricmeasures in the same subject for sensitive
detection of tau pathology. These imaging changes may reﬂect very
early local markers of tau pathology in the thalamus, but we cannot
rule out that some of these differences may also be secondary to the
large tau pathology in the forebrain structures, many of which are
known to project to the thalamus. This may be important as we know
that tau aggregates can transfer and propagate/spread within synaptic
circuits (Clavaguera et al., 2009; de Calignon et al., 2012). There
is post-mortem evidence in AD for this regional spread (Zhou Gennatas
et al., 2012) and more recent neuroimaging studies in human AD
suggest “epicentres” (Zhou et al., 2012) or “nodes” (Raj et al., 2012)
that may link to network dysfunction.
In conclusion, this study demonstrates the value of non-invasive
multi-parametric quantitative MRI for sensitive detection of tau pathol-
ogy in the rTg4510 model of AD. These novel data represent a platform
for future longitudinal and therapeutic efﬁcacy studies in this model.
The 5-tiered measurement approach is directly translatable and merits
application in clinical populations to investigate the pattern of MR
changes in regions known to follow the well-deﬁned stages of NFT pro-
gression. Estimates of perfusion and diffusion can detect changes in
healthy tissue in a region of low NFT density (2.3 cells/mm2) with no
detectable atrophy which provides promise for the use of these markers
to identify and track subjects early in the Alzheimer's disease continuum.Funding
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